Our variant ascertainment algorithm, VAAL, uses massively parallel DNA sequence data to identify differences between bacterial genomes with high sensitivity and specificity. VAAL detected B98% of differences (including large insertiondeletions) between pairs of strains from three species while calling no false positives. VAAL also pinpointed a single mutation between Vibrio cholerae genomes, identifying an antibiotic's site of action by identifying sequence differences between drug-sensitive strains and drug-resistant derivatives.
Bacteria are enormously important for studies ranging from human medicine to environmental ecology. Even within species of bacteria, there is enormous genetic variation. The ability to routinely compare the genomes of many bacterial strains and identify their differences is thus of tremendous value to understanding their impact on human health and biology.
In this work we addressed two key applications: comparison of a new strain with a previously sequenced reference strain and comparison of a laboratory-induced mutant strain to the parental strain. An example of the former application is a comparison of multiple clinical isolates of Mycobacterium tuberculosis, which might differ in their resistance to various drugs. We expected to find genetic variation at several sites across the genome; the critical genetic differences underlying a phenotype would become apparent if they are observed in multiple strains. An example of the latter application is an analysis of a mutant strain resistant to a particular antibiotic. One would expect to find only one mutation in such a comparison, which could be used to pinpoint the antibiotic's target. This is valuable because there is currently no simple way to identify the sites of action of a drug.
Pioneering work on these applications had used available technology, often in multistage processes. For example, whole-genome shotgun Sanger sequencing had been followed by directed resequencing 1,2 , or an initial microarray screen had been followed by a validation microarray experiment 3 . In each case the second stage had been designed based on the results of the first stage. With the advent of massively parallel sequencing methods 4-7 , a streamlined approach is feasible, facilitating routine comparison at dramatically lower cost. Indeed, a substantial amount of sequence for a bacterial strain can now be generated for roughly $1,000, and the costs are likely to drop.
To take advantage of the new inexpensive data types and deliver highly accurate results, computational methods are needed that can find the full spectrum of variation, including insertions and deletions of arbitrary size, as all may be phenotypically important. Yet a single base change can confer antibiotic resistance in bacteria, a 'needle in the haystack' problem that exemplifies the need for high specificity. Although initial work [8] [9] [10] [11] [12] [13] on this problem has been promising, there has been no systematic and controlled investigation of general variation detection using new technology data. For example, insertion-deletion (indel) detection has not yet been systematically tested on real data.
We developed a new variant ascertainment algorithm, VAAL, and applied it to several comparisons, including comparisons between naturally occurring strains and between antibiotic-sensitive and derived antibiotic-resistant strains. In each case truth data (knowledge of the genome sequence or of the antibiotic target) were available, facilitating rigorous assessment of answers. For each strain we generated a single lane of unpaired 36-base reads from the Illumina platform, thereby minimizing costs. The source code for VAAL and all experimental datasets are made freely available (Supplementary Software and Supplementary Data online). We carried out all applications of VAAL with the distributed version of the code, using default arguments.
VAAL takes as input short reads from a 'sample genome' and a known sequence for a related 'reference genome' . VAAL assembles the reads 14, 15 , using the reference genome for assistance. This 'assisted assembly' indicates which bases are 'trusted' and which are not. By comparing the assisted assembly of the RECEIVED 10 JULY; ACCEPTED 24 NOVEMBER; PUBLISHED ONLINE 14 DECEMBER 2008; DOI:10.1038/NMETH.1286 sample genome to the reference genome, VAAL deduces as output a list of differences between them.
There are several steps in the algorithm (Supplementary Methods and Supplementary Fig. 1 online) . Briefly, we assign each sample read an approximate position in the reference genome and then group reads by position. Next we assemble each group, then 'glue' the assemblies along regions in which sample and reference genomes agree, yielding a single assembly of the sample genome. Next we call bases in the assembly trusted if they are strongly supported by the reads. Finally, to identify polymorphisms, we compare the sample read data assembly to the reference genome and identify differences between them that are within the trusted parts of the assembly. To do this, we identify regions containing disagreements between the assembly and the reference that are flanked by regions where the two sequences agree. These disagreements include substitutions, insertions, deletions and more complex changes (multiple nearby differences) that we refer to as composites; VAAL reports all as polymorphisms. Here we treated composites as single polymorphisms, but VAAL also provides output in which each composite is parsed into substitutions, insertions and deletions.
We designed VAAL to discover sequence differences between related genomes, with high sensitivity and specificity. To demonstrate this, we compared sequence data from 'sample genomes' to finished reference sequences for related isolates of the same species. We used finished genomes so the true answer was known in all cases. The dataset for this work consisted of 36 base Illumina reads from three previously sequenced bacterial genomes (Staphylococcus aureus, Escherichia coli and M. tuberculosis; Supplementary  Table 1 online).
Genomes contain repetitive sequences longer than the reads, within which polymorphisms cannot be called unambiguously. To avoid these ambiguities, VAAL defines uncallable regions of the genome in which polymorphisms cannot be called unambiguously with the given data, declaring the remainder of the genome to be callable ( Supplementary Methods) . The size of the callable fraction depends on the amount of duplicated sequence in the genome. It also depends on read length and the minimum overlap, K (in this work, 28). For the data and genomes used here, the callable fraction was 91.6-96.7% ( Table 1 ). In evaluating the algorithm, we defined the set of callable polymorphisms, which reflect unambiguous differences, as those residing in the callable regions and used them to evaluate sensitivity ( Table 1) .
First, we used VAAL to compare the sample reads to the finished sequences of the genomes from which they were generated. Notably, VAAL called no polymorphisms, demonstrating high specificity as any reported polymorphisms would have been false positives.
Next we performed the between-strain comparison using VAAL and evaluated the performance on the callable polymorphisms ( Table 1) . For E. coli (moderate G+C content, 51%), VAAL identified 100% of callable polymorphisms. The called insertions included three exceeding the read length, of 93, 390 and 970 base pairs. For S. aureus (low G+C content, 33%), VAAL identified 499% of substitutions, 95% of insertion-deletions (indels) and 90% of composites. For M. tuberculosis (high G+C content, 66%), VAAL identified 97% of substitutions, 83% of indels and 95% of composites.
Briefly, VAAL showed high sensitivity in finding nearly all of the possible callable polymorphisms. In no cases did it call any false positives. In two cases it called bona fide polymorphisms that lay outside the set of callable polymorphisms. We explain the mechanism for these rare events in Supplementary Methods. VAAL performed well even on complex composite events (Supplementary Methods). We also investigated the failure modes of the few polymorphisms that VAAL missed and how coverage influences the fraction of missed polymorphisms (Supplementary Methods and Supplementary Tables 2 and 3 online) .
We note that the three bacterial genomes examined have 33-66% G+C content, a range encompassing B80% of previously sequenced bacteria (http://www.ncbi.nlm.nih.gov/genomes/lproks. cgi/). Testing behavior over a range of sequence G+C content is important because behaviors of sequencing systems vary considerably as a function of G+C content.
We next attempted to discover single base differences between a parental strain and a derived mutant strain. We sequenced both the parental and mutant strains and compared them to a known reference strain.
We compared each of five Vibrio cholerae isolates sensitive to the antibiotic rifampicin with derived rifampicin-resistant isolates (Supplementary Methods), anticipating that each resistant isolate would likely have acquired a single resistance mutation. To do this, for each of the five sensitive-resistant pairs, we sequenced both strains and assembled them with VAAL, assisted by a single finished reference ( Supplementary Table 4 online). Then we used VAAL to compare the two assemblies to each other and obtained a list of differences ( Table 2) . For all five sensitive-resistant pairs, we found exactly one difference in the entire genome. In all cases, the difference was in the rpoB gene, which encodes the b subunit of RNA polymerase, rifampicin's known target (Supplementary Results online).
We compared VAAL to other algorithms (Supplementary Results and Supplementary Tables 5-8 online): MAQ 13 and VAAL called different numbers of single-nucleotide polymorphisms (SNPs), suggesting distinct advantages; MAQ did not call indels from unpaired reads, as in this study; a Velvet 16 -VAAL hybrid yielded results comparable to VAAL at high coverage but inferior results at lower coverage, as expected because Velvet assembles de novo.
Sensitive and specific polymorphism discovery with singlemolecule sequencing data is a major open problem. VAAL approaches it by grouping reads and then performing a local assembly, taking into account the relationships between individual reads and the reference, and between reads themselves. Thus, the algorithm can find differences (for example, long insertions) that cannot be found by methods dependent on alignments of single reads to the reference. Notably, VAAL does not contain special rules for each polymorphism type (SNP, SNP cluster, indel and others) and thus can discover all differences without presuppositions.
Here we used VAAL to detect sequence differences between related bacterial strains, with very high sensitivity and no observed false positives, and also to identify a single mutation conferring antibiotic resistance, without prior knowledge of its location. The first application enabled rapid discovery of variations underlying medically or biologically important phenotypes. The second application enabled the rapid discovery of the targets of antibiotics by analyzing antibiotic-resistant mutants. Although VAAL requires relatively high genome sequence coverage, this is inexpensive. Sequencing costs are now sufficiently low that analysis of hundreds or thousands of bacterial strains is practical.
In its present form, VAAL works on haploid genomes, providing highly sensitive and specific polymorphic detection for bacteria. Generalization of the algorithm to large, complex, diploid genomes is the next goal. In particular, it should soon be practical to sequence targeted subsets (such as regions or exons) from hundreds of human DNA samples.
Note: Supplementary information is available on the Nature Methods website. 
